BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garcia PL, Miller AL, Yoon KJ. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. Cancers (Basel) 2020;12:E1327. [PMID: 32456018 DOI: 10.3390/cancers12051327] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Mallya K, Gautam SK, Aithal A, Batra SK, Jain M. Modeling pancreatic cancer in mice for experimental therapeutics. Biochim Biophys Acta Rev Cancer 2021;1876:188554. [PMID: 33945847 DOI: 10.1016/j.bbcan.2021.188554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zhang J, Yan X, Liu R, Wu S, Liu Q, Li J, Ma J. Bevacizumab is an Efficient Therapeutic Approach with Low Side Effects in Patient-Derived Xenografts of Adenoid Cystic Carcinoma of the Lacrimal Gland. CMAR 2022;Volume 14:1023-32. [DOI: 10.2147/cmar.s352623] [Reference Citation Analysis]
3 Gonzalez-Valdivieso J, Garcia-Sampedro A, Hall AR, Girotti A, Arias FJ, Pereira SP, Acedo P. Smart Nanoparticles as Advanced Anti-Akt Kinase Delivery Systems for Pancreatic Cancer Therapy. ACS Appl Mater Interfaces 2021;13:55790-805. [PMID: 34788541 DOI: 10.1021/acsami.1c14592] [Reference Citation Analysis]
4 Melzer MK, Breunig M, Arnold F, Wezel F, Azoitei A, Roger E, Krüger J, Merkle J, Schütte L, Resheq Y, Hänle M, Zehe V, Zengerling F, Azoitei N, Klein L, Penz F, Singh SK, Seufferlein T, Hohwieler M, Bolenz C, Günes C, Gout J, Kleger A. Organoids at the PUB: The Porcine Urinary Bladder Serves as a Pancreatic Niche for Advanced Cancer Modeling. Adv Healthc Mater 2022;11:e2102345. [PMID: 35114730 DOI: 10.1002/adhm.202102345] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Heinrich MA, Mostafa AMRH, Morton JP, Hawinkels LJAC, Prakash J. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. Adv Drug Deliv Rev 2021;174:265-93. [PMID: 33895214 DOI: 10.1016/j.addr.2021.04.018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
6 Parsels LA, Zhang Q, Karnak D, Parsels JD, Lam K, Willers H, Green MD, Rehemtulla A, Lawrence TS, Morgan MA. Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02621-3. [PMID: 34348175 DOI: 10.1016/j.ijrobp.2021.07.1708] [Reference Citation Analysis]
7 Hoare O, Fraunhoffer N, Elkaoutari A, Gayet O, Bigonnet M, Roques J, Nicolle R, McGuckin C, Forraz N, Sohier E, Tonon L, Wajda P, Boyault S, Attignon V, Tabone-Eglinger S, Barbier S, Mignard C, Duchamp O, Iovanna J, Dusetti NJ. Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models. Cancers (Basel) 2021;13:2473. [PMID: 34069519 DOI: 10.3390/cancers13102473] [Reference Citation Analysis]
8 Stoof J, Harrold E, Mariottino S, Lowery MA, Walsh N. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives. Front Cell Dev Biol 2021;9:749490. [PMID: 34712667 DOI: 10.3389/fcell.2021.749490] [Reference Citation Analysis]
9 Golan T, Atias D, Stossel C, Raitses-Gurevich M. Patient-derived xenograft models of BRCA-associated pancreatic cancers. Adv Drug Deliv Rev 2021;171:257-65. [PMID: 33617901 DOI: 10.1016/j.addr.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Hirai K, Watanabe S, Nishijima N, Shibata K, Hase A, Yamanaka T, Inazu M. Molecular and Functional Analysis of Choline Transporters and Antitumor Effects of Choline Transporter-Like Protein 1 Inhibitors in Human Pancreatic Cancer Cells. Int J Mol Sci 2020;21:E5190. [PMID: 32707889 DOI: 10.3390/ijms21155190] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Pratt HG, Steinberger KJ, Mihalik NE, Ott S, Whalley T, Szomolay B, Boone BA, Eubank TD. Macrophage and Neutrophil Interactions in the Pancreatic Tumor Microenvironment Drive the Pathogenesis of Pancreatic Cancer. Cancers (Basel) 2021;14:194. [PMID: 35008355 DOI: 10.3390/cancers14010194] [Reference Citation Analysis]
12 Murase Y, Ono H, Ogawa K, Yoshioka R, Ishikawa Y, Ueda H, Akahoshi K, Ban D, Kudo A, Tanaka S, Tanabe M. Inhibitor library screening identifies ispinesib as a new potential chemotherapeutic agent for pancreatic cancers. Cancer Sci 2021;112:4641-54. [PMID: 34510663 DOI: 10.1111/cas.15134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 van Weerden WM. Patient-Derived Xenograft Models in Cancer Research. Cancers (Basel) 2021;13:815. [PMID: 33669175 DOI: 10.3390/cancers13040815] [Reference Citation Analysis]
14 Miquel M, Zhang S, Pilarsky C. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol 2021;9:748631. [PMID: 34778259 DOI: 10.3389/fcell.2021.748631] [Reference Citation Analysis]
15 Choi YS, Kim MJ, Choi EA, Kim S, Lee EJ, Park MJ, Kim MJ, Kim YW, Ahn HS, Jung JY, Jang G, Kim Y, Kim H, Kim K, Kim JY, Hong SM, Kim SC, Chang S. Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis. Proc Natl Acad Sci U S A 2022;119:e2119048119. [PMID: 35858411 DOI: 10.1073/pnas.2119048119] [Reference Citation Analysis]
16 Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Yao J, Yang M, Atteh L, Liu P, Mao Y, Meng W, Li X. A pancreas tumor derived organoid study: from drug screen to precision medicine. Cancer Cell Int 2021;21:398. [PMID: 34315500 DOI: 10.1186/s12935-021-02044-1] [Reference Citation Analysis]